JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $6,854,000 | -22.8% | 2,928,900 | 0.0% | 0.13% | -21.1% |
| Q2 2022 | $8,875,000 | -54.3% | 2,928,900 | +2.4% | 0.16% | -48.9% |
| Q1 2022 | $19,419,000 | -18.7% | 2,859,900 | 0.0% | 0.32% | +2.6% |
| Q4 2021 | $23,880,000 | +21.0% | 2,859,900 | +7.7% | 0.31% | +41.5% |
| Q3 2021 | $19,731,000 | +35.1% | 2,655,600 | +23.7% | 0.22% | +46.6% |
| Q2 2021 | $14,602,000 | -22.0% | 2,147,400 | +17.8% | 0.15% | -15.4% |
| Q1 2021 | $18,728,000 | – | 1,823,600 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |